The Effects of Different Compatibilities of Qing'e Formula on Scopolamine-induced Learning and Memory Impairment in the Mouse

Xiao-Ping Zheng^a, Fang-Di Hu^a, Li Yang^{b,c}, Yu-Ling Ma^a, Bo-Lu Sun^a, Chang-Hong Wang^{b,c}, Zheng-Tao Wang^{b,c}

^aSchool of Pharmacy, Lanzhou University, Lanzhou 730000, ^bThe MOE Key Laboratory for Standardization of Chinese Medicines and the Key Laboratory for Pharmacology of Compound Chinese Medicine of Shanghai, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, ^cResearch Center for Traditional Chinese Medicine of Complexity System, Shanghai University of Traditional Chinese Medicine, Shanghai 201302, China

Abstract

Background: The Qing'e formula (QEF) is a well-known traditional Chinese prescription that has been clinically employed for treatment of bone disease for hundreds of years. **Objective:** The present study aims to observe the effects of different compatibilities of QEF on the scopolamine-induced learning and memory impairment in the mouse, and further to explore its action mechanisms and compatibility rationality. **Materials and Methods:** The learning and memory alterations in the mouse were evaluated using the step-down test and Morris water maze (MWM) test; the acetylcholinesterase (AChE) activity and brain-derived neurotrophic factor (BDNF) expression in the hippocampus were measured using colorimetric method or immunohistochemistry. **Results:** The results showed that different compatibilities of QEF significantly prolonged latency in the step-down test, shortened escape latency in the navigation test, increased the percentage of residence time, and the percentage of swimming distance in the target quadrant in the probe trial session. In addition, our results also found that different compatibilities of QEF remarkably inhibited AChE activity and increased BDNF expression in the hippocampus of mice. What's more, the group after being treated with whole recipe (QF) showed the highest level of improvement. **Conclusions:** These findings not only suggest that QEF may effectively ameliorate cognitive deficits through inhibiting AChE activity and increasing BDNF expression in the hippocampus but also elucidate the rationality of QEF.

Keywords: Acetylcholinesterase, brain-derived factor, Learning and memory, Qing'e formula

INTRODUCTION

Alzheimer disease (AD) is a devastating neurodegenerative disorder affecting the millions of people. It reduces the ability of the individual to remain independent, brings a heavy burden on caregivers, and substantially increases health-care costs.^[1] The pathophysiology of AD is complex and unclear. There are many hypotheses to explain AD, such as cholinergic hypothesis,^[2] amyloid hypothesis,^[3] and tau hypothesis.^[4] Among them, the loss of cholinergic is more recognized, and its pathogenesis is widely studied at present.^[5,6] Therefore, current treatment prescribed in AD patients, for example, donepezil, is acetylcholinesterase inhibitors (AChEIs). However, these AChEIs have short half-lives and severe side effects,^[7] such as nausea, gastrointestinal upset, and diarrhea, which are the most frequent and important side effects of these therapies.

Access this article online		
Quick Response Code:	Website: www.wjtcm.net	
	DOI: 10.4103/wjtcm.wjtcm_8_17	

Traditional Chinese medicine (TCM) has been clinically used in China for thousands of years and has played an indispensable role in prevention and treatment of diseases, especially for complicated and chronic conditions.^[8,9] Now in TCM, several herbs and ingredients are combined according to strict rules to form prescriptions, which are referred to as formulas (*fāng jì* in Chinese). In general, a classic formula is composed of four elements, i.e., an sovereign medicinal

> Address for correspondence: Prof. Fang-Di Hu, School of Pharmacy, Lanzhou University, Lanzhou 730000, China. E-mail: hufd@lzu.edu cn

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

© 2017 World Journal of Traditional Chinese Medicine | Published by Wolters Kluwer - Medknow

Received: 22-11-2016, Accepted: 24-03-2017

How to cite this article: Zheng XP, Hu FD, Yang L, Ma YL, Sun BL, Wang CH, *et al.* The effects of different compatibilities of qing'e formula on scopolamine-induced learning and memory impairment in the mouse. World J Tradit Chin Med 2017;3:12-7.

with one or more minister, assistant, and courier medicinals according to their different roles in the formula. Each formula comprises of one to several drugs.^[10] Moreover, the multiple components in TCM formulas exert a synergistic therapeutic effect, which is known as "formula compatibility."^[11] Reasonable formula compatibility can achieve an overall effect of optimized combination. In recent years, TCM formulas have attracted a wide interest from Chinese and international researchers because of their few side effects, multicomponents, multipathways, and multitargets.

Qing'e formula (QEF), originally recorded in "Taiping Huimin Heji Ju Fang (Prescriptions from the Great Peace Imperial Grace Pharmacy)" in the Song Dynasty (10th century CE), which is a classic traditional Chinese medicine recipe comprised of eucommniae cortex (EC), psoraleae fructus (PF), juglandis semen (JS), and garlic rhizoma (GR). It is officially recorded in Chinese pharmacopoeia for kidney-tonifying and bone-strengthening.^[12] QEF has been showed to have the efficacy of enhancing immune function, improving microcirculation, and being analgesic, antibacterial, and anti-inflammatory. It is famous in the clinical practice for its efficacy in the treatment of postmenopausal osteoporosis,^[13] coronary heart disease,^[14] acute exacerbation stage of chronic bronchitis,^[15] chloasma^[16] in recent years. Modern pharmacology research shown that EC had anti-amnesic activity through the inhibition of acetylcholinesterase (AChE) and protection of brain-derived neurotrophic factor (BDNF) expression.^[17] Isobavachalcone and bavachinin from PF also could improve learning and memory by inhibiting Ab42 aggregation.^[18] The JS extract could enhance the acetylcholine, acetylcholine transferase activity, and suppress AChE activity to prevent and treat AD.^[19] Allicin could effectively improve spatial learning and memory function in AD mice.^[20] However, the effects of QEF and its different compatibilities on learning and memory have rarely been reported.

In this paper, the effects of different compatibilities of QEF on the scopolamine-induced learning and memory impairment in mice were evaluated. The results demonstrated the mechanisms and compatible regularity of QEF for improving learning and memory.

MATERIALS AND METHODS

Animals

 20 ± 2 g male Kunming mice were obtained from Experimental Animal Center of Lanzhou University (Lanzhou, China) (Certificate of Conformity: SCXK (Gan) 2013-0002). All animals were housed in an air-conditioned room at temperature of $22^{\circ}C \pm 2^{\circ}C$ and a relative humidity of $50\% \pm 10\%$ with a 12 h dark-light cycle (light on from 7:00 to 19:00). All the animals were allowed to have free access to water and food. All experimental procedures were conducted in accordance with the guidelines for the use of experimental animals and were approved by the Institutional Review Committee on Animal Care.

Chemicals and reagents

EC, PF, JS, and GR were purchased from the Sichuan Xinghehua TCM Electuary Co., Ltd. (Sichuan, China) and identified by Prof. Li-Hong Wu, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine. Scopolamine hydrobromide (Scop) was obtained from Shanghai Harvest Pharmaceutical Co., Ltd. Donepezil hydrochloride was obtained from Eisai (China) pharmaceutical Co., Ltd. The assay kit for AChE was purchased from the Nanjing Jiancheng Biotech Company. Rabbit polyclonal anti-BDNF antibody was purchased from Abcam, UK. Other chemicals were all analytical reagents.

Preparation of the extracts of Qing'e formula and its different compatibilities

The extracts of QEF and its different compatibilities were obtained as follows: (a) EC; (b) EC + PF; (c) EC + JS; (d) EC + GR; (e) EC + PF + JS + GR (QF); and (f) PF. Six different compatibilities of QEF were infiltrated with 8-fold mass of ethanol-water (75:25, v/v), respectively, and then extracted under reflux for three times, 3 h and each time, and filtrated with doubled absorbent gauze after each extraction. The six groups of the combined filtrate were evaporated to dryness, and the residues were reconstituted in 5% ethanol-water, respectively.

Experimental procedures

The random number table was used to divide the experimental mice into nine groups (1) Control, (2) Model, (3) Positive, (4) EC, (5) EC + PF, (6) EC + JS, (7) EC + GR, (8) QF, and (9) PF, 15 mice in each group. The control group and model group were orally administered with the same dose of water, the positive group was orally administered with donepezil (1 mg/kg body weight), and other groups were orally administered with corresponding physic extracts (2 g/kg body weight), consecutively for 21 days. The control group was injected intraperitoneally (i.p.) with saline while the other eight groups were administered with Scop (2 mg/kg i. p.) before the behavioral experiments.

Step-down test

The inhibitory avoidance training apparatus was composed of a transparent box $(32 \text{ cm} \times 22 \text{ cm} \times 33 \text{ cm})$ with a stainless-steel grid floor and an elevated rubber platform (4.5 cm in diameter and 4.5 cm in height) on the left side wall of the training box apparatus. Its floor was made of parallel 0.1 cm caliber stainless steel bars spaced 0.5 cm apart. The step-down test was carried out in 2 days including training and retention sessions. On the first training day, mice were allowed to adapt for 3 min in the box. After 3 min, electric shocks were delivered and mice jumped on the platform to avoid stimulation. If the animals stepped down from the platform (error trial), they were exposed to an electric foot shock (36 V, AC). After 24 h, latency was assessed again and recorded as the learning grade (latency), which was taken as a measure of memory retention.

Donepezil (1 mg/kg, p. o.) and the extracts of different compatibilities of QEF (2 g/kg, p. o.) or vehicle (the same volume of water) solution were administered to mice 40 min before the acquisition trials. Each acquisition trial was carried out 10 min after a single Scop treatment (2 mg/kg, i.p.).

Morris water maze task

The apparatus of MWM task consisted of a circular pool (40 cm in height and 80 cm in diameter) filled with water at $23^{\circ}C \pm 2^{\circ}C$. Leukophyll was added to the pool water to make it opaque. A clear plexiglas platform (10 cm in diameter \times 17.5 cm in height) was submerged 1 cm below the water surface. The pool was divided into four equal quadrants and each quadrant was marked by a different visual cue. The platform was randomly placed in one quadrant during the experiment. The whole experiment lasted 6 days. On the 1st day, mice were allowed a 120 s habituation session in the pool without the platform. In the following 4 days, each mouse received four 120 s learning trials with the platform, with 60 s resting periods between trials. For each learning trial, mice were placed into the water facing the pool wall at one of four points of entry. The escape latency, the time required to locate the submerged platform, was recorded for each trial. If the mice were unable to locate the platform within 120 s, it was led to the platform and allowed to rest for 60 s. The escape latency in these cases was recorded as 120 s. After the completion of the learning trials, the platform was removed from the pool. The percentage of residence time and the percentage of swimming distance during platform quadrant were recorded, which would be the detection index of spatial memory.

Drug administration was identical to that of the step-down test.

Acetylcholinesterase activity assay

After the behavioral tests, the mice were sacrificed, and the hippocampus was carefully stripped from cerebral cortex and washed with ice-cold normal saline before it was dried with filter paper and weighed. The clean hippocampus was snap frozen in refrigerator and stored at -80°C until analysis. The hippocampus was rapidly dissected and homogenized in ice-cold normal saline to make 10% tissue homogenate that was followed with centrifuge at 3000 rpm for 15 min at 4°C. The supernatant was used for determination of AChE. The AChE activity was measured according to the instructions of the assay kit.

Immunohistochemical staining

Following the behavioral test, mice were deeply anesthetized with 0.4% pentobarbital sodium (10 mg/kg body weight), then the hippocampus was harvested on an ice board and fixed in a bottle with 4% paraformaldehyde solution for 24 h at 4°C. Hippocampus was embedded in paraffin wax and then cut into sagittal slices of 8 μ m thickness by vibratome. Afterward, sections of every group were dewaxed and rehydrated. Next, sections were boiled in 0.01 mol citric acid buffer for 10 min. After cooling, these sections were incubated in 3% H₂O₂ for 5 min and then in 10% goat serum in PBS for 10 min. The sections were then incubated with

rabbit anti-BDNF (1:500) overnight at room temperature and subsequently exposed to biotinylated goat anti-rabbit IgG and streptavidin-peroxidase complex. Sections were visualized by a reaction to 3,3'-diaminobenzidine tetrachloride kit (DAB, ZSGB-BIO, China) followed by dehydration and mounting on gelatin-coated slides.

Statistical analysis

Statistical analyses were performed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). All data were expressed as (mean \pm SD) a nonparametric test (Kruskal–Wallis test) was used to evaluate the difference between all groups. *P* < 0.05 was considered statistically significant.

RESULTS

Effects of different compatibilities of Qing'e formula on Scop-induced learning and memory impairment in the step-down test

Learning and memory impairments in Scop-treated and control animals were evaluated using the step-down test [Figure 1a]. As shown in Figure 1b, the step-down latency of model group mice in the step-down test was significantly shorter than that of control group mice (P < 0.01). Figure 1b showed that the short step-down latency by Scop was significantly reversed after orally administered with donepezil, the extracts of EC, EC + PF, EC + GR, QF, and PF (P < 0.05 or P < 0.01). There was no distinct difference between the model group and the EC + JS treatment group. Of note, the efficacy of QF



Figure 1: The effects of different compatibility of Qing'e formula on Scop-induced learning andmemory impairment in the Step-down test. (a) Apparatus of the Step-down test; (b) Latency of the memory retention. **P < 0.01 versus control group; #P < 0.05, ##P < 0.01 versus model group

group was better than that of other compatibilities, but there were no distinct differences between QF group and other compatibilities.

Effects of different compatibilities of Qing'e formula on Scop-induced learning and memory impairment in the Morris water maze task

Spatial memory performance was assessed over successive 4 days using the hidden platform [Figure 2a], and a probe trial was conducted with no platform on the 6th day. In the navigation test, the model group exhibited longer escape latency than the control group [Figure 2b, P < 0.01]. Compared with model group, donepezil and the extracts of EC, EC + PF, EC + JS, EC + GR, QF, and PF significantly shortened the escape latency of Scop-treated mice in varying degrees [Figure 2b, P < 0.05 or P < 0.01]. Interestingly, the escape latency of QF group was less than that of other compatibility groups, but only the escape latency of EC + JS group had statistical significance compared with the QF group [Figure 2b, P < 0.05].

In the probe test, the residence time percent and swimming distance percent in the target quadrant of model group were significantly less than control group [Figure 2c and d, P < 0.01]. At the same time, donepezil and the extracts of EC, EC + PF, EC + JS, EC + GR, QF, PF not only dramatically increased the percentage of residence time [Figure 2c, P < 0.05 or P < 0.01] but also rose the percentage of swimming distance by comparison with model group [Figure 2d, P < 0.05 or P < 0.01]. Interestingly, the percentage of residence time and the percentage of swimming distance of QF group were greater than that of other compatibility groups, but only the percentage of residence time and the percentage of swimming distance of Swimming distance of the percentage of residence time and the percentage of swimming distance of the percentage of residence time and the percentage of swimming distance of the percentage of th

EC and EC + JS groups had statistical significance compared with the QF group [Figure 2c and d, P < 0.05 or P < 0.01].

Effects of different compatibilities of Qing'e formula on the acetylcholinesterase activity

As shown in Table 1, the activity of AChE in model group mice significantly increased in comparison with control group mice (P < 0.01). Donepezil and the extracts of EC, EC + PF, EC + JS, EC + GR, QF, PF significantly inhibited AChE activity in the hippocampus by comparing with the model group (P < 0.01). Simultaneously, distinct differences were observed between the QF group and other compatibilities groups (P < 0.01), that is to say, QF could show the highest level of improvement by inhibiting AChE activity.

Effects of different compatibilities of Qing'e formula on the expression of brain-derived factor

The hippocampus of control group had more positive neurons of BDNF, and the positive expression stained darker [Figure 3a], while the positive expression stained lighter and looser in the model group [Figure 3b]. Meanwhile, the positive expression of BDNF increased in donepezil group and different compatibilities of QEF groups by comparison with model group [Figure 3c-i and Table 1]. Moreover, the positive expression of BDNF in QF group was higher than that of other treatment groups except the EC + PF group [Table 1].

DISCUSSION

As we all known, scopolamine is a nonselective centrally acting muscarinic receptor antagonist and impairs learning and memory in both rodents and humans.^[21,22] This experimental model of memory impairment has been extensively used in



Figure 2: The effects of different compatibility of Qing'e formula on theScop-induced learning andmemory impairment in Morris water-maze task. (a) The apparatus for Morris watermaze; (b) The escape latencytime to find the submerged platform; (c) The residence timepercent; (d) swimming distance percent during platform quadrant. *P < 0.05, **P < 0.01 versus control group; *P < 0.05, **P < 0.01 versus model group; $^{\triangle}P < 0.05$, **P < 0.01 versus QF group



Figure 3: The effects of different compatibility of Qing'e formula on the expression of brain-derived neurotrophic factor (\times 400). (a) Control group; (b) Model group; (c) Positive group; (d) EC group; (e) EC + PF group; (f) EC + JS group; (g) EC + GR group; (h) QF group; (i) PF group. EC: Eucommniae cortex, PF: Psoraleae fructus, JS: Juglandis semen, GR: Garlic rhizoma

Table 1: The effects of different compatibilities of Qing'e formula on acetylcholinesterase activity and brain-derived neurotrophic factor expression in hippocampus (mean±standard deviation)

Group	AChE (U/mg protein)	BDNF
Control	0.41±0.11	0.26±0.02
Model	1.06±0.19**	0.18±0.01**
Donepezil	0.48±0.14 ^{##}	0.23±0.01##
EC	0.66±0.21***,##,\$\$	0.22±0.05 [#]
EC + PF	0.53±0.24 ^{##,\$\$}	0.26±0.01##
EC + JS	0.55±0.10* ^{,##,SS}	0.18±0.01**. ^{\$\$}
EC + GR	0.56±0.08**,##,\$\$	0.21±0.01*
QF	0.31±0.08##	0.25±0.02##
PF	0.64±0.08** ^{,##,\$\$}	0.19±0.02**,§

AChE: Acetylcholinesterase, BDNF: Brain-derived neurotrophic factor, EC: *Eucommniae Cortex*, JS: *Juglandis Semen*, PF: *Psoraleae Fructus*, GR: *Garlic Rhizoma*, QF: Whole recipe. *P < 0.05, **P < 0.01 vs control group; *P < 0.05, ##P < 0.01 vs model group; *P < 0.05; \$\$P < 0.01 vs QF group

research for screening of drugs with potential therapeutic efficacy on dementia. Improvement of learning and memory impairment is usually evaluated through the behavioral test, such as passive avoidance task, step-down test, and Morris water maze task.^[23,24] Step-down test needs activating cholinergic system to complete the task, so it is an ideal model to study the influence of cholinergic system on learning and memory.^[25] Besides, Morris water maze task is a classic experiment for investigating learning and memory. Therefore, step-down test and Morris water maze task finally have been used in this study to evaluate the improvement of learning and memory after drug treatment. Based on the results of this study, it was found that different compatibilities of QEF significantly prolonged latency in the step-down test and shortened escape

latency in the navigation test. In the probe test, treatment with different compatibilities of QEF dramatically increased the percentage of residence time and the percentage of swimming distance in the target quadrant in the scopolamine-induced mice. In addition, the QF combination further enhanced this effect.

Learning and memory are the most advanced functions in brain. The process of learning and memory contains complex neural physiological and biochemical mechanisms, particularly the cholinergic system, which has the closest relationship with learning and memory.^[26,27] Acetylcholine is the most relevant neurotransmitter with learning and memory, the key enzymes of whose synthesis and metabolism are choline acetyltransferase and AChE. Numerous drugs maintain high levels of acetylcholine in the synaptic cleft to enhance cholinergic neurotransmission and improve the learning and memory ability by promoting synthesis or inhibition of metabolic enzymes. BDNF is an important member of the neurotrophic factors and plays a crucial role in synaptic neurotransmission and plasticity.^[28] This study also confirmed that BDNF was one of the key proteins in the process of learning and memory formation.^[29] In this experiment, we assessed the effects of different compatibilities of QEF on scopolamine-induced AChE activity and BDNF expression in the hippocampus, showing that scopolamine significantly increased AChE activity and reduced BDNF expression levels in the hippocampus. These results were in agreement with those of previous studies.^[30,17] Our study results indicated that different compatibilities of OEF inhibited AChE activity and increased BDNF expression in the hippocampus. Among them, the improvement of QF was stronger than other partial compatibility groups.

CONCLUSION

To sum up, different compatibilities of QEF improved learning and memory deficits in scopolamine-induced mouse models through suppressing AChE activity and increasing BDNF expression. Among all compatibility groups, the group that was treated with QF extract showed the highest level of improvement. Therefore, this paper clarified compatibility rationality of QEF and provided a new possible drug in AD treatment. In addition, our study also found that the extract of PF alone could significantly improve the learning and memory ability of model mice, which was consistent with the experiment of Chen,^[18] but its possible mechanism and active ingredients still need further study.

Acknowledgment

The authors acknowledge financial support from the Opening Project of Shanghai Key Laboratory of Complex Prescription (Shanghai University of Traditional Chinese Medicine, 13DZ2272300, ZK-1501).

Financial support and sponsorship Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

- Knebl JA, Patki D. Recruitment of subjects into clinical trials for Alzheimer disease. J Am Osteopath Assoc 2010;110:S43-9.
- Yoo JH, Valdovinos MG, Williams DC. Relevance of donepezil in enhancing learning and memory in special populations: A review of the literature. J Autism Dev Disord 2007;37:1883-901.
- Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H, *et al.* Down's syndrome and Alzheimer's disease: Towards secondary prevention. Nat Rev Drug Discov 2012;11:655-6.
- Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y, et al. Tau PET imaging in Alzheimer's disease. Curr Neurol Neurosci Rep 2014;14:500.
- Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011;221:555-63.
- Rafii MS, Aisen PS. Advances in Alzheimer's disease drug development. BMC Med 2015;13:62.
- Casey DA, Antimisiaris D, O'Brien J. Drugs for Alzheimer's disease: Are they effective? J Clin Pharm Ther 2010;35:208.
- 8. Cheung F. TCM: Made in china. Nature 2011;480:S82-3.
- 9. Grayson M. Traditional Asian medicine. Nature 2011;480:S81.
- Fan TP, Yeh JC, Leung KW, Yue PY, Wong RN. Angiogenesis: From plants to blood vessels. Trends Pharmacol Sci 2006;27:297-309.
- 11. Zhang A, Sun H, Yuan Y, Sun W, Jiao G, Wang X, et al. An in vivo analysis of the therapeutic and synergistic properties of Chinese medicinal formula Yin-Chen-Hao-Tang based on its active constituents. Fitoterapia 2011;82:1160-8.
- National Pharmacopoeia Committee. China Pharmacopoeia. Beijing: Chemical Industry Press; 2015.
- Li P, Shen L, Yang Y. Clinical research of Qing'e pill in treatment of postmenopausal osteoporosis with kidney deficiency and blood stasis syndrome. Res Integr Tradit Chin W Med 2014;6:281-5.
- Yang DY, Duan XZ, Zhang YH. Clinical studies on Qingewan jiajianfang (QEWJJF) in treating post-menopausal women with angina. Chin J Nat Med 2001;1:7.
- Huang YJ, Jiang SS. A summary on 80 cases of chronic bronchitis in acute stage treated by Liujunzi decoction combining Qing'e decoction. J Tradit Chin Med 2010;26:1-2.
- Chen L, Zheng Y, Gao J, Zhang JM. Effect of yangyanqing'e wan on the mRNA transcription level of tyrosinase in B-16 murine melanoma cells.

Chin J Dermatol Venerol Integr Traditional W Med 2005;4:220-2.

- Kwon SH, Ma SX, Joo HJ, Lee SY, Jang CG. Inhibitory effects of *Eucommia ulmoides* oliv. Bark on scopolamine-induced learning and memory deficits in mice. Biomol Ther (Seoul) 2013;21:462-9.
- Chen X, Yang Y, Zhang Y. Isobavachalcone and bavachinin from *Psoraleae fructus* modulate aβ42 aggregation process through different mechanisms *in vitro*. FEBS Lett 2013;587:2930-5.
- Zhou LS, Zhu SX, Wang LS. Experimental study of Walnut kernel extracts on Ach, ChAT and AChE activities in Alzheimer's disease rats model. Chin J Hosp Pharm 2011;31:446-9.
- Hu XQ, Li XH, Zheng YF. The effects of Allicin on Alzheimers disease and cerebral tissue antioxidant in mouse. Chin J Gerontol 2010;30:944-5.
- Sharma D, Puri M, Tiwary AK, Singh N, Jaggi AS. Antiamnesic effect of stevioside in scopolamine-treated rats. Indian J Pharmacol 2010;42:164-7.
- 22. Hescham S, Temel Y, Casaca-Carreira J, Arslantas K, Yakkioui Y, Blokland A, *et al.* A neuroanatomical analysis of the effects of a memory impairing dose of scopolamine in the rat brain using cytochrome c oxidase as principle marker. J Chem Neuroanat 2014;59-60:1-7.
- Gacar N, Mutlu O, Utkan T, Komsuoglu Celikyurt I, Gocmez SS, Ulak G, *et al.* Beneficial effects of resveratrol on scopolamine but not mecamylamine induced memory impairment in the passive avoidance and Morris water maze tests in rats. Pharmacol Biochem Behav 2011;99:316-23.
- Zhu L, Zhang L, Zhan L, Lu X, Peng J, Liang L, et al. The effects of Zibu Piyin Recipe components on scopolamine-induced learning and memory impairment in the mouse. J Ethnopharmacol 2014;151:576-82.
- Kunisawa K, Nakashima N, Nagao M, Nomura T, Kinoshita S, Hiramatsu M, *et al.* Betaine prevents homocysteine-induced memory impairment via matrix metalloproteinase-9 in the frontal cortex. Behav Brain Res 2015;292:36-43.
- Weinberger NM, Miasnikov AA, Chen JC. The level of cholinergic nucleus basalis activation controls the specificity of auditory associative memory. Neurobiol Learn Mem 2006;86:270-85.
- Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer's disease. Arch Pharm Res 2013;36:375-99.
- Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 2013;14:7-23.
- Barnes P, Thomas KL. Proteolysis of proBDNF is a key regulator in the formation of memory. PLoS One 2008;3:e3248.
- Becker R, Giacobini E, Elble R, McIlhany M, Sherman K. Potential pharmacotherapy of Alzheimer disease. A comparison of various forms of physostigmine administration. Acta Neurol Scand Suppl 1988;116:19-32.